Puig, Luis http://orcid.org/0000-0001-6083-0952
Costanzo, Antonio
de Jong, Elke M. G. J.
Torres, Tiago
Warren, Richard B.
Wapenaar, Robert
Wegner, Sven
Gorecki, Patricia
Gramiccia, Talia
Jazra, Maria
Buyze, Jozefien
Conrad, Curdin
Clinical trials referenced in this document:
Documents that mention this clinical trial
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials
https://doi.org/10.1007/s13555-024-01123-1
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial
https://doi.org/10.1007/s13555-024-01245-6
Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
https://doi.org/10.1007/s13555-023-01012-z
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
https://doi.org/10.1007/s40257-023-00816-1
Funding for this research was provided by:
Janssen
Article History
Accepted: 22 August 2023
First Online: 7 October 2023
Declarations
:
: This article was sponsored by Janssen. Medical writing and editorial support were funded by Janssen.
: LP reports consulting fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Novartis, Pfizer, Sandoz, Samsung-Bioepis, and UCB; payment or honoraria from Janssen, Lilly, Novartis, and UCB; support for attending meetings and/or travel from Janssen and UCB; grants received from Abbvie, Almirall, Amgen, Boehringer Ingelheim, Janssen, Leo-Pharma, Lilly, Novartis, and UCB; and a non-financial relationship with the International Psoriasis Council. AC reports consulting fees from AbbVie and UCB; payment or honoraria from AbbVie, Almirall, Amgen, Galderma, Janssen, Lilly, Novartis, and UCB; support for attending meetings and/or travel from AbbVie; and participation on a Data Safety Monitoring Board and/or Advisory Board for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Janssen, Leo-Pharma, Lilly, Novartis, and UCB. EMGJdJ reports receiving research grants from AbbVie, BMS, Janssen Pharmaceutica, Leo Pharma, Lilly, Novartis, and UCB; and has acted as a consultant, paid speaker, and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis or eczema, including AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Celgene, Galapagos, Janssen Pharmaceutica, Leo Pharma, Lilly, Novartis, Sanofi, and UCB. TT reports consulting fees from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz, and Sanofi; payment or honoraria from AbbVie, Almirall, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Sandoz, and Sanofi; support for attending meetings and/or travel from AbbVie, Almirall, Janssen, Leo Pharma, MSD, Novartis, Pfizer, and Sanofi; and participation on a Data Safety Monitoring Board and/or Advisory Board for Samsung-Bioepis. RBW reports consulting fees from AbbVie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DiCE, GSK, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Sun Pharma, UCB, and UNION; payment or honoraria from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Sun Pharma, and UCB; and grants received from AbbVie, Almirall, Janssen, Leo, Lilly, Novartis, Pfizer, and UCB. RW holds stock at Johnson & Johnson and was a full-time employee of Janssen at the time of the study. SW is a full-time employee of and owns stock at Janssen. PG is a full-time employee at Janssen. TG is a full-time employee at Janssen. MJ holds stocks at Johnson & Johnson and is a full-time employee at Janssen. JB is a full-time employee at Janssen. CC reports consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung, Sanofi, and UCB; payment or honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB; participation on a Data Safety Monitoring Board and/or Advisory Board for AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, MSD, Novartis, Pfizer, and UCB; grants received from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, and Pfizer; and leadership and/or fiduciary roles for the European Society for Dermatological Research and the Swiss Society for Dermatology and Venereology.
: This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Given that this is a post-hoc analysis of the VOYAGE 1 clinical trial, ethical approval was not needed.
: Patients provided their written consent to participate in the study after having been informed about the nature and purpose of the study, participation/termination conditions, and risks and benefits of treatment.
: Not applicable.
: The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at ExternalRef removed. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at ExternalRef removed.
: LP, AC, TT, RBW, RW, SW, PG, TG, MJ, and CC contributed to conceptualization of the study; TT, RW, SW, PG, MJ, and CC contributed to the development and design of the methodology; TT, SW, and JB contributed to the data curation; TT, RW, and JB contributed to formal data analysis; SW, PG, and MJ provided funding acquisition and financial support for the project; LP, TT, PG, and CC conducted the research; RBW, SW, PG, MJ, and CC planned, directed, and coordinated research activity; PG provided resources and analysis tools; RW contributed to the programming and implementation of computer programs; AC, TT, RBW, SW, PG, and MJ provided supervision of the research, including mentorship; AC, TT, SW, PG, MJ, and JB provided validation of the results; LP, AC, TT, SW, MJ, JB, and CC contributed to data visualization and presentation; SW, PG, and TG contributed to writing the initial draft of the manuscript; LP, AC, EMGJdJ, TT, RBW, RW, SW, PG, TG, JB, and CC provided critical review at each stage the manuscript’s development. All authors approved the final version of the manuscript.
: Not applicable.